|Day Low/High||0.09 / 0.11|
|52 Wk Low/High||0.06 / 10.30|
Single-Center Retrospective Data Also Demonstrate Therapy Extends Progression-Free Survival by 9 Months
Retrospective Analysis of Outcomes with Investigational Melphalan/HDS and Commercial CHEMOSAT® Projects Median Overall Survival to be 657 Days; 1,207 Days for Responders
Delcath Systems, Inc. (DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced the pricing of an underwritten public offering of 425,000...
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on developing safe and effective treatments for primary and metastatic liver cancers, announces that results from two single-institution...
These under-$10 stocks are within range of triggering breakout trades.
Trade-Ideas LLC identified Delcath Systems (DCTH) as a weak on high relative volume candidate
When a stock makes a large move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Northwest Bio received good news from Germany in February but didn't tell investors until Monday.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
These under-$10 stocks look ready to trade higher from current levels.
Momentum traders don't understand FDA regulations.
Investors in Delcath Systems Inc. saw new options begin trading this week, for the March 2014 expiration.
This week, David Peltier answers questions about two model portfolio names and two other specific low-dollar stocks.
Holzer Holzer & Fistel LLC reminds investors of upcoming deadlines for applications to serve as lead plaintiff in securities class action lawsuits against Delcath Systems, Inc.
The Law Offices of Todd M. Garber announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of a class (the “Class”) comprising all ...
These under-$10 stocks look poised to trade higher from current levels.
An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.
This group of contestants have nearly perfect records picking FDA and European drug approvals.
Stock futures are looking to rebound from losses in the prior session.
Join TheStreet's Adam Feuerstein as he live blogs FDA advisory panels for Aveo Oncology and Delcath Systems
Delcath's liver-tumor device uses a filter that FDA says does not work.
It's a big week for Aveo and Delcath, starting Tuesday with FDA reviews of their respective cancer products.
TheStreet Sr. Columnist Adam Feuerstein says FDA reviews for cancer drugs from Aveo and Delcath are the next big thing in biotech.
A list of stock-moving biotech catalysts includes FDA drug approvals, clinical trial results and closely-followed medical meetings.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Contestants in TheStreet's FDA Drug Approval Contest think well of Sarepta, Navidea and Biogen, less so about Arena, Aveo and Delcath.
Who will be the premier prognosticator of FDA drug approvals in 2013?
Stocks making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.